SummaryPancreatic ductal adenocarcinomas (PDAs) are characterized by a robust fibroinflammatory response. We show here that this desmoplastic reaction generates inordinately high interstitial fluid pressures (IFPs), exceeding those previously measured or theorized for solid tumors, and induces vascular collapse, while presenting substantial barriers to perfusion, diffusion, and convection of small molecule therapeutics. We identify hyaluronan, or hyaluronic acid (HA), as the primary matrix determinant of these barriers and show that systemic administration of an enzymatic agent can ablate stromal HA from autochthonous murine PDA, normalize IFP, and re-expand the microvasculature. In combination with the standard chemotherapeutic, gemcitabin...
Pancreatic ductal adenocarcinoma (PDAC) elicits a dense stromal response that blocks vascular access...
Desmoplasia describes the deposition of extensive extracellular matrix and defines primary pancreati...
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to treat. It is re...
Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell...
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascul...
Pancreatic ductal adenocarcinomas (PDAs) are notoriously aggressive and resistant to treatment. They...
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascul...
Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in more than 250,...
AbstractProgression of cancer is often associated with interactions between cancer cells and extrace...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases to affect humans, regardl...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies and is the fourth...
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes among cancers with a 5-years s...
Pancreatic ductal adenocarcinoma is an especially deadly disease having the lowest 5-year survival r...
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by an intense desmoplastic stro...
Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense desmoplastic stroma tha...
Pancreatic ductal adenocarcinoma (PDAC) elicits a dense stromal response that blocks vascular access...
Desmoplasia describes the deposition of extensive extracellular matrix and defines primary pancreati...
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to treat. It is re...
Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell...
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascul...
Pancreatic ductal adenocarcinomas (PDAs) are notoriously aggressive and resistant to treatment. They...
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascul...
Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in more than 250,...
AbstractProgression of cancer is often associated with interactions between cancer cells and extrace...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases to affect humans, regardl...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies and is the fourth...
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes among cancers with a 5-years s...
Pancreatic ductal adenocarcinoma is an especially deadly disease having the lowest 5-year survival r...
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by an intense desmoplastic stro...
Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense desmoplastic stroma tha...
Pancreatic ductal adenocarcinoma (PDAC) elicits a dense stromal response that blocks vascular access...
Desmoplasia describes the deposition of extensive extracellular matrix and defines primary pancreati...
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to treat. It is re...